Market Research Logo

Optic Neuropathy - Pipeline Review, H2 2016

Optic Neuropathy - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Optic Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy
    • The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects
    • The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Optic Neuropathy
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Optic Neuropathy Overview
    Therapeutics Development
    Pipeline Products for Optic Neuropathy - Overview
    Pipeline Products for Optic Neuropathy - Comparative Analysis
    Optic Neuropathy - Therapeutics under Development by Companies
    Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes
    Optic Neuropathy - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Optic Neuropathy - Products under Development by Companies
    Optic Neuropathy - Products under Investigation by Universities/Institutes
    Optic Neuropathy - Companies Involved in Therapeutics Development
    Amgen Inc.
    BioAxone BioSciences, Inc.
    Inotek Pharmaceuticals Corporation
    Ironwood Pharmaceuticals, Inc.
    PharmatrophiX, Inc.
    Quark Pharmaceuticals, Inc.
    Regenera Pharma Ltd.
    Optic Neuropathy - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    BA-240 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IWP-953 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LM-22A4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NT-501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    QPI-1007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RPh-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trabodenoson - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    WSTB-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Optic Neuropathy - Dormant Projects
    Optic Neuropathy - Product Development Milestones
    Featured News & Press Releases
    Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
    Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
    Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
    Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
    Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
    Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
    Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Optic Neuropathy, H2 2016
    Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Optic Neuropathy - Pipeline by Amgen Inc., H2 2016
    Optic Neuropathy - Pipeline by BioAxone BioSciences, Inc., H2 2016
    Optic Neuropathy - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
    Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
    Optic Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2016
    Optic Neuropathy - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
    Optic Neuropathy - Pipeline by Regenera Pharma Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Optic Neuropathy - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Optic Neuropathy, H2 2016
    Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report